RELAPSES IN INTERIM PET NEGATIVE LIMITED STAGE HODGKIN LYMPHOMA PATIENTS RECEIVING ABVD WITH OR WITHOUT RADIOTHERAPY–ANALYSIS OF EORTC/FIL/LYSA H10 AND UK NCRI RAPID TRIALS

Introduction: Randomized trials H10 and RAPID were designed to assess whether radiotherapy (RT) can be safely omitted in newly diagnosed limited-stage Hodgkin lymphoma (HL) patients who are interim PET-negative (iPETneg) after 2 (H10) or 3 (RAPID) cycles of ABVD. Despite differences in inclusion criteria and treatment, in both studies relapses were more frequent after chemotherapy only (C) than after combined modality treatment (C+RT), even in...